NO20060771L - Benzimidazol, benztiazol og benzoksazol derivater og deres anvendelse som LTA4H modulatorer - Google Patents

Benzimidazol, benztiazol og benzoksazol derivater og deres anvendelse som LTA4H modulatorer

Info

Publication number
NO20060771L
NO20060771L NO20060771A NO20060771A NO20060771L NO 20060771 L NO20060771 L NO 20060771L NO 20060771 A NO20060771 A NO 20060771A NO 20060771 A NO20060771 A NO 20060771A NO 20060771 L NO20060771 L NO 20060771L
Authority
NO
Norway
Prior art keywords
group
benztiazole
benzimidazole
lta4h
benzoxazole derivatives
Prior art date
Application number
NO20060771A
Other languages
English (en)
Norwegian (no)
Inventor
Frank Urban Axe
James P Edwards
Jianmei Wei
Cheryl A Grice
Scott D Bembenek
Christopher R Butler
Anne M Fourie
Brad M Savall
Kevin L Tays
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20060771L publication Critical patent/NO20060771L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Manufacturing & Machinery (AREA)
  • Ceramic Engineering (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Materials Engineering (AREA)
  • Structural Engineering (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO20060771A 2003-07-28 2006-02-17 Benzimidazol, benztiazol og benzoksazol derivater og deres anvendelse som LTA4H modulatorer NO20060771L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49071003P 2003-07-28 2003-07-28
PCT/US2004/024309 WO2005012297A1 (en) 2003-07-28 2004-07-27 Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators

Publications (1)

Publication Number Publication Date
NO20060771L true NO20060771L (no) 2006-04-21

Family

ID=34115427

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20060771A NO20060771L (no) 2003-07-28 2006-02-17 Benzimidazol, benztiazol og benzoksazol derivater og deres anvendelse som LTA4H modulatorer
NO20060823A NO20060823L (no) 2003-07-28 2006-02-20 Benzimidazol, benztiazol og benzoksazol derivater og deres anvendelse som LTA4H modulatorer

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20060823A NO20060823L (no) 2003-07-28 2006-02-20 Benzimidazol, benztiazol og benzoksazol derivater og deres anvendelse som LTA4H modulatorer

Country Status (29)

Country Link
US (2) US20050043379A1 (uk)
EP (2) EP1660491B1 (uk)
JP (2) JP4726238B2 (uk)
KR (2) KR101149379B1 (uk)
CN (2) CN100591679C (uk)
AR (2) AR045729A1 (uk)
AT (2) ATE403654T1 (uk)
AU (2) AU2004261610B2 (uk)
BR (2) BRPI0413072A (uk)
CA (2) CA2534212A1 (uk)
CY (1) CY1108560T1 (uk)
DE (2) DE602004016002D1 (uk)
DK (2) DK1660491T3 (uk)
ES (2) ES2311858T3 (uk)
HK (2) HK1092790A1 (uk)
HR (2) HRP20060039A2 (uk)
IL (1) IL173372A (uk)
MY (1) MY145080A (uk)
NO (2) NO20060771L (uk)
NZ (2) NZ544938A (uk)
PL (2) PL1660491T3 (uk)
PT (2) PT1660492E (uk)
RU (2) RU2359970C2 (uk)
SG (2) SG129449A1 (uk)
SI (2) SI1660492T1 (uk)
TW (2) TW200520756A (uk)
UA (2) UA87986C2 (uk)
WO (2) WO2005012297A1 (uk)
ZA (2) ZA200601720B (uk)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0413072A (pt) * 2003-07-28 2006-10-03 Janssen Pharmaceutica Nv moduladores de lta4h
EA200702128A1 (ru) * 2005-03-31 2008-04-28 Янссен Фармацевтика Н.В. Фенильные и пиридильные модуляторы lta4h
PL1877379T3 (pl) 2005-04-13 2013-06-28 Astex Therapeutics Ltd Pochodne hydroksybenzamidu i ich wykorzystanie, jako inhibitorów hsp90
EP1717235A3 (en) * 2005-04-29 2007-02-28 Bioprojet Phenoxypropylpiperidines and -pyrrolidines and their use as histamine H3-receptor ligands
BRPI0615449A2 (pt) * 2005-09-02 2011-05-17 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método de tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de sst do subtipo 5 e uso desses compostos
US7402684B2 (en) * 2005-09-21 2008-07-22 Decode Genectics Ehf. Biaryl substituted heterocycle inhibitors of LTA4H for treating inflammation
AU2006333522A1 (en) * 2005-12-21 2007-07-12 Decode Genetics, Ehf. Biaryl nitrogen heterocycle inhibitors of LTA4H for treating inflammation
WO2007073405A1 (en) * 2005-12-21 2007-06-28 Decode Genetics Ehf N-linked aryl heteroaryl inhibitors of lta4h for treating inflammation
AU2006327245A1 (en) 2005-12-21 2007-06-28 Decode Genetics Ehf Biaryl substituted nitrogen containing heterocycle inhibitors of LTA4H for treating inflammation
WO2007079078A1 (en) 2005-12-29 2007-07-12 Bayer Schering Pharma Aktiengesellschaft Diamine derivatives as inhibitors of leukotriene a4 hydrolase
EP1987009A1 (en) * 2006-01-30 2008-11-05 Euro-Celtique S.A. Cyclourea compounds as calcium channel blockers
US7754725B2 (en) 2006-03-01 2010-07-13 Astex Therapeutics Ltd. Dihydroxyphenyl isoindolymethanones
US7951829B2 (en) * 2006-05-03 2011-05-31 Janssen Pharmaceutica Nv Benzimidazole modulators of VR1
US8299095B2 (en) * 2006-06-16 2012-10-30 H. Lundbeck A/S Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition and uses thereof
WO2008019284A1 (en) * 2006-08-04 2008-02-14 Decode Genetics Ehf Phenoxymethylalkyne inhibitors of lta4h for treating inflammation
US8115005B2 (en) 2006-08-04 2012-02-14 Decode Genetics Ehf. Pyrazolylphenyl and pyrrolylphenyl inhibitors of LTA4H for treating inflammation
WO2008019306A2 (en) * 2006-08-04 2008-02-14 Decode Genetics Ehf Aryl amino acid derivatives as inhibitors of lta4h (leukotriene a4 hydrolase) for treating inflammation
WO2008044029A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
US9730912B2 (en) 2006-10-12 2017-08-15 Astex Therapeutics Limited Pharmaceutical compounds
WO2008044041A1 (en) 2006-10-12 2008-04-17 Astex Therapeutics Limited Pharmaceutical combinations
GB0620259D0 (en) 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
TW200906396A (en) * 2007-02-14 2009-02-16 Janssen Pharmaceutica Nv LTA4H modulators and uses thereof
PT2134704E (pt) * 2007-03-08 2010-12-13 Irm Llc Compostos e composições como moduladores da actividade de gpr119
WO2008120710A1 (ja) * 2007-03-30 2008-10-09 Panasonic Electric Works Co., Ltd. 活動強度計
PE20091017A1 (es) * 2007-10-31 2009-07-16 Janssen Pharmaceutica Nv Diaminas en puente o fusionadas sustituidas con arilo como moduladores de leucotrieno a4 hidrolasa
CA2705294C (en) * 2007-11-16 2016-05-17 Abbott Laboratories Methods of treating arthritis by the administration of substituted benzenesulfonamides
MX2010011154A (es) * 2008-04-11 2010-12-21 Janssen Pharmaceutica Nv Tiazolopiridin-2-iloxi-fenilo y tiazolopirazin-2-iloxifenilaminas como moduladores de la leucotrieno a4 hidrolasa.
GB0806527D0 (en) 2008-04-11 2008-05-14 Astex Therapeutics Ltd Pharmaceutical compounds
CN105622580B (zh) 2008-04-28 2019-06-21 詹森药业有限公司 作为脯氨酰羟化酶抑制剂的苯并咪唑
WO2010132599A1 (en) * 2009-05-14 2010-11-18 Janssen Pharmaceutica Nv Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene a4 hydrolase
CN102442962A (zh) * 2010-11-10 2012-05-09 江苏德峰药业有限公司 1-烷基四氮唑的生产方法
CN102442961A (zh) * 2010-11-10 2012-05-09 江苏德峰药业有限公司 1-甲基四氮唑的生产方法
AU2012328763A1 (en) 2011-10-25 2014-05-01 Janssen Pharmaceutica Nv Meglumine salt formulations of 1-(5,6-dichloro-1H-benzo(d)imidazol-2-yl)-1H-pyrazole-4-carboxylic acid
CA2905340C (en) 2013-03-12 2022-05-31 Celtaxsys, Inc. Low dose oral formulations of acebilustat
AU2014240042C1 (en) 2013-03-14 2019-09-05 Celltaxis, Llc Inhibitors of leukotriene A4 hydrolase
BR112015022864A8 (pt) 2013-03-14 2019-11-26 Celtaxsys Inc composto, composição farmacêutica e uso dos mesmos
AU2014239585B2 (en) * 2013-03-14 2019-04-04 Celtaxsys, Inc. Inhibitors of leukotriene A4 hydrolase
ES2651858T3 (es) * 2013-12-17 2018-01-30 Eli Lilly & Company Derivados de amina cíclica de fenoxietilo y su actividad como moduladores del receptor EP4
US10633336B2 (en) 2014-12-19 2020-04-28 The Broad Institute, Inc. Dopamine D2 receptor ligands
WO2016100823A1 (en) 2014-12-19 2016-06-23 The Broad Institute, Inc. Dopamine d2 receptor ligands
PT3307734T (pt) 2015-06-09 2020-02-25 Abbvie Inc Moduladores de recetores nucleares (ror) para o tratamento de doenças inflamatórias e autoimunes
MX2019006123A (es) 2016-12-21 2019-08-12 Hoffmann La Roche Metodo para glicomanipulacion in vitro de anticuerpos.
CN107663192B (zh) * 2017-11-03 2019-05-10 梯尔希（南京）药物研发有限公司 一种雷贝拉唑杂质的制备方法
CA3102077A1 (en) 2018-05-31 2019-12-05 Sanjeev AHUJA Method of reducing pulmonary exacerbations in respiratory disease patients
EP3908278A4 (en) * 2019-01-11 2022-09-28 Naegis Pharmaceuticals Inc. LEUCOTRIENE SYNTHESIS INHIBITORS
CN110026557B (zh) * 2019-05-28 2021-08-27 南方科技大学 一种混合固体颗粒重熔的直写装置及成型方法
MX2023005943A (es) * 2020-11-19 2023-08-11 Telo Therapeutics Inc Compuestos y composiciones de moléculas pequeñas.
CN113683491A (zh) * 2021-09-01 2021-11-23 王传良 一种4-(2-溴乙基)苯酚的制备方法
CN113735798B (zh) * 2021-09-27 2022-07-12 安徽美致诚药业有限公司 一种盐酸罗沙替丁醋酸酯的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873346A (en) * 1985-09-20 1989-10-10 The Upjohn Company Substituted benzothiazoles, benzimidazoles, and benzoxazoles
CA1319144C (en) * 1986-11-14 1993-06-15 Quirico Branca Tetrahydronaphthalene derivatives
IT1240598B (it) * 1990-03-13 1993-12-17 Mini Ricerca Scient Tecnolog Derivati amminici ad azione antifungina
US5585492A (en) * 1994-10-11 1996-12-17 G. D. Searle & Co. LTA4 Hydrolase inhibitors
IL117149A0 (en) * 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
US5925654A (en) * 1997-03-12 1999-07-20 G.D. Searle & Co. LTA4 , hydrolase inhibitors
TR200002445T2 (tr) * 1998-02-25 2000-12-21 Genetics Institute, Inc. Fosfolipaz inhibitörleri.
US6514964B1 (en) * 1999-09-27 2003-02-04 Amgen Inc. Fused cycloheptane and fused azacycloheptane compounds and their methods of use
US20040110757A1 (en) * 2002-03-21 2004-06-10 Thomas Arrhenius Flt-1 ligands and their uses in the treatment of diseases regulatable by angiogenesis
BRPI0413072A (pt) * 2003-07-28 2006-10-03 Janssen Pharmaceutica Nv moduladores de lta4h
US7541466B2 (en) * 2003-12-23 2009-06-02 Genzyme Corporation Tetrahydroisoquinoline derivatives for treating protein trafficking diseases
CN101128196B (zh) * 2005-03-16 2013-01-02 Meda制药有限及两合公司 用于治疗呼吸系统疾病的抗胆碱能药和白三烯受体拮抗剂的组合
TW200906396A (en) * 2007-02-14 2009-02-16 Janssen Pharmaceutica Nv LTA4H modulators and uses thereof

Also Published As

Publication number Publication date
CY1108560T1 (el) 2014-04-09
BRPI0412345A (pt) 2006-10-03
EP1660491B1 (en) 2008-08-06
WO2005012297A1 (en) 2005-02-10
AU2004261628B2 (en) 2011-05-12
PL1660492T3 (pl) 2009-01-30
PT1660491E (pt) 2008-10-10
KR20060054408A (ko) 2006-05-22
TW200523255A (en) 2005-07-16
ES2311858T3 (es) 2009-02-16
ATE403654T1 (de) 2008-08-15
IL173372A0 (en) 2006-06-11
AR045729A1 (es) 2005-11-09
CA2534212A1 (en) 2005-02-10
EP1660492B1 (en) 2008-08-20
ZA200601716B (en) 2007-05-30
SG129449A1 (en) 2007-02-26
AU2004261628A1 (en) 2005-02-10
HRP20060041A2 (en) 2006-11-30
CN1860117A (zh) 2006-11-08
JP2007500703A (ja) 2007-01-18
US20050043379A1 (en) 2005-02-24
CN100591679C (zh) 2010-02-24
NO20060823L (no) 2006-03-15
EP1660491A1 (en) 2006-05-31
KR101149379B1 (ko) 2012-06-28
AU2004261610A1 (en) 2005-02-10
HRP20060041B1 (hr) 2014-06-06
NZ544970A (en) 2009-02-28
UA87986C2 (uk) 2009-09-10
JP4726238B2 (ja) 2011-07-20
HK1090359A1 (en) 2006-12-22
AU2004261610B2 (en) 2010-05-20
DE602004016002D1 (de) 2008-10-02
RU2006102508A (ru) 2006-07-27
KR20060057593A (ko) 2006-05-26
RU2006102510A (ru) 2006-07-27
WO2005012296A1 (en) 2005-02-10
BRPI0413072A (pt) 2006-10-03
DE602004015620D1 (de) 2008-09-18
RU2359970C2 (ru) 2009-06-27
JP2007500706A (ja) 2007-01-18
CA2534228A1 (en) 2005-02-10
ATE405562T1 (de) 2008-09-15
HK1092790A1 (en) 2007-02-16
AR045730A1 (es) 2005-11-09
TW200520756A (en) 2005-07-01
DK1660491T3 (da) 2008-11-10
RU2373204C2 (ru) 2009-11-20
US20050043378A1 (en) 2005-02-24
WO2005012297A9 (en) 2007-01-04
TWI362383B (en) 2012-04-21
SG130192A1 (en) 2007-03-20
ES2313079T3 (es) 2009-03-01
IL173372A (en) 2010-11-30
MY145080A (en) 2011-12-15
HRP20060039A2 (en) 2006-08-31
CN1856490A (zh) 2006-11-01
PT1660492E (pt) 2008-11-13
ZA200601720B (en) 2007-11-28
UA82888C2 (en) 2008-05-26
PL1660491T3 (pl) 2009-01-30
NZ544938A (en) 2009-05-31
EP1660492A1 (en) 2006-05-31
SI1660492T1 (sl) 2009-02-28
SI1660491T1 (sl) 2009-02-28
DK1660492T3 (da) 2008-11-03

Similar Documents

Publication Publication Date Title
NO20060771L (no) Benzimidazol, benztiazol og benzoksazol derivater og deres anvendelse som LTA4H modulatorer
DK1070056T3 (da) Phthalazinon-PDE III/IV-inhibitorer
NO20075384L (no) Tiadiazolsubstituerte kumarinderivater og deres anvendelse som leukotrienbiosynteseinhibitorer.
TW200605884A (en) CETP inhibitors
TW200732336A (en) Alyphactic heterocyclic compounds
NO20075623L (no) Benzodioksan- og benzodioksolanderivater og deres anvendelse
NO20063925L (no) Indazolderivater som inhibitorer av hormonsensitiv lipase
NO331165B1 (no) Derivater av dioksan-2-alkylkarbamater, fremgangsmate for fremstilling derav og anvendelse av de samme for fremstilling av medikamenter
NO20072963L (no) 5-substituerte kinolin- og isokinolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som betennelseshemmere
CO6260074A2 (es) Compuestos de 5-(4-(halo-alcoxi)-fenil)-pirimidin-2-amina y composiciones como inhibidores de cinasa
ATE258930T1 (de) Dihydrobenzifurane
NO20080110L (no) Benzimidazolderivativer som 5-HT6,5-HT24
ATE399168T1 (de) Imidazopyridin-derivate und ihre verwendung als induzierbare no-synthase inhibitoren
DE602006018359D1 (de) Heterocyclische derivate, deren herstellung und therapeutische verwendung
DE69922009D1 (de) Imidazolverbindungen und ihre verwendung als adenosindeaminase-inhibitoren
TNSN06456A1 (en) Cetp inhibitors
NO20033131L (no) Anvendelse av 2-amino-4-pyridylmetyl-tiazolinderivater som inhibitorer forinduktibel NO-syntase
SE9904676D0 (sv) Novel compounds
TR199903296T2 (en) Bile�ikler.
BR0317126A (pt) Derivados de indol e o uso dos mesmos como ligantes de 5-ht
NO963208L (no) Anvendelse av 1,3,2-benzoditiazol-1-oksyder som mikrobiocider for beskyttelse av tekniske materialer såvel som visse 1,3,2-benzoditiazol-1-oksyder
ATE236887T1 (de) Arylsulfonamid-substituierte benzimidazolderivate und ihre verwendung als tryptase-inhibitoren
SE0000477D0 (sv) Novel compounds
ATE340175T1 (de) Imidazo(4,5-böchinolinderivate und ihre verwendung als inhibitoren der induzierbaren no- synthase
ATE247092T1 (de) Arylsulfonamid-substituierte benzimidazolderivate ihre verwendung als tryptase-inhibitoren

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application